<DOC>
<DOCNO>EP-0619299</DOCNO> 
<TEXT>
<INVENTION-TITLE>
1-(Phenyl)-3-[omega-(amino)-alkoxyimino]-alk-1-ene derivatives, a process for preparing them as well as medicaments containing them and the use of them.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31135	A61K31135	A61K3115	A61K3115	A61K31357	A61K31357	A61K3136	A61K31395	A61K31395	A61K3140	A61K3140	A61K3144	A61K3144	A61K314406	A61K314406	A61K314418	A61K314418	A61K31445	A61K31445	A61K31495	A61K31495	A61P100	A61P104	A61P2500	A61P2520	C07C25100	C07C25132	C07C25158	C07D20700	C07D20708	C07D21300	C07D21330	C07D29500	C07D29500	C07D29508	C07D295088	C07D31700	C07D31758	C07D40500	C07D40512	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	C07C	C07C	C07C	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P1	A61P1	A61P25	A61P25	C07C251	C07C251	C07C251	C07D207	C07D207	C07D213	C07D213	C07D295	C07D295	C07D295	C07D295	C07D317	C07D317	C07D405	C07D405	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
A subject-matter of the invention are 1-(Phenyl)-3-[ω-(amino)-alkoxyimino]-alk-1-ene 

derivatives of general formula 

wherein 

R₁ and R₂
independently each stands for hydrogen, halogen 
or a C₁₋₄ alkoxy group or together represent 

a 3,4-methylenedioxy group, 
R
stands for C₁₋₈ alkyl, 
R₃
represents hydrogen, C₁₋₄ alkyl or hydroxy, 
R₄ and R₅
independently each represents hydrogen, a 
C₁₋₁₂ alkyl group, optionally substituted by  

 
hydroxy, or a C₂₋₁₂ alkenyl or C₃₋₆ cycloalkyl 

group,
 

óóóor 
R₄ and R₅
together with the nitrogen atom to which 
they are attached form a 4- to 7-membered 

heterocyclic ring, optionally comprising an 
oxygen, sulfur or a fu
rther nitrogen atom, 
which latter optionally may carry a phenyl, 

benzyl or C₁₋₄ alkyl substituent
 

óóóand 
A
represents a valency bond or a -CH₂-group, 
 
as well as stereo and optically active isomers and their mixtures, 

acid-addition salts and quaternary ammonium derivatives 
thereof. 
Furthermore the invention is concerned with a process for 
preparing these compounds as well as medicaments containing them 

and the use of them for preparing medicaments, particularly having 
ulcus and gastric-acid-secretion inhibiting and anxiolytic 

effects. 
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
The invention is concerned with novel basic oxime ethers 
with useful pharmacological, particularly ulcus and gastric--acid-secretion 
inhibiting and anxiolytic, effects, a process 
for preparing them as well as medicaments containing these 
compounds and the use of them. Some alkoxyimino derivatives carrying a basic group as 
substituent have been known in the art. The fluorene derivative "IPS-339" of formula 
and the methyl cyclopropylketone derivative of formula 
known as Falintolol, exhibit beta-adrenergic blocking activity.  The compound of formula 
known as Peradoxime, possesses blood pressure reducing activity. Peraclopone of formula 
reduces the level of lipids. British patent specification No. 1,493,222 describes the 
compound of formula  exhibiting local anaesthetic and antiparkinsonic activities. Belgian patent specification 886,471 describes benzothiophene 
derivatives of formula 
wherein 
Lrepresents a benzothiophene group
 
and Bstands for a secondary amino group.  
The compounds exhibit beta-adrenergic blocking and antiarrhythmic 
activities. Published PCT patent application 8,402,908 describes carbostyrylketoxime 
derivatives exhibiting not only beta-adrenergic  
 
blocking activity but antiglaucomic activity as well. Belgian patent specification 838,440 describes beta-adrenergic 
blocking, blood-pressure reducing and cardiovascular 
compounds of formula f, wherein L represents a polycyclic ring, 
e. g. fluorene, indane, xanthane or tetrahydronaphthalene ring, 
or phenyl or naphthyl ketone and B always stands for a secondary 
amino group. US patent specification 4,652,586 relates to compounds of 
formula f, wherein L is fluorene and B is a secondary amino 
group. The compounds reduce the inner pressure of eye and exhibit 
selective β₂-adrenergic antagonistic effect. European patent specification No. 82,058 describes compounds 
of formula 
wherein R₁ represents cyclohexyl, phenyl, benzyl or C₁₋₄ alkyl, 
R₂ stands for piperidyl and R₃ and R₄ each represents straight 
or branched chained C₁₋₄ alkyl, or together with the nitrogen 
atom to which they are attached form a 4- to 7-membered saturated 
heterocyclic ring, optionally containing a further nitrogen 
or an oxygen atom, and n is an integer from 1 to 4. The 
compounds exhibit spasmolytic and antihistamine activities. European patent specification 82,059 relates to oxime ether 
derivatives of formula  wherein R₁ and R₂ each represents hydrogen, halogen or C₁₋₄ alkyl 
or together form a methylenedioxy group, R₃ is hydrogen or phenyl, 
which
</DESCRIPTION>
<CLAIMS>
1-(Phenyl)-3-[ω-(amino)-alkoxyimino]-alk-1-ene derivatives 

of general formula 
 

wherein 
R₁ and R₂independently each stands for hydrogen, halogen 

or a C₁₋₄ alkoxy group or together represent 
a 3,4-methylenedioxy group, Rstands for C₁₋₈ alkyl, R₃represents hydrogen, C₁₋₄ alkyl or hydroxy, R₄ and R₅independently each represents hydrogen, a 

C₁₋₁₂ alkyl group, optionally substituted by 
hydroxy, or a C₂₋₁₂ alkenyl or C₃₋₆ cycloalkyl 

group, 
   or R₄ and R₅together with the nitrogen atom to which 

 
they are attached form a 4- to 7-membered 

heterocyclic ring, optionally comprising an 
oxygen, sulfur or a further nitrogen atom, 

which latter optionally may carry a phenyl, 
benzyl or C₁₋₄ alkyl substituent 

   and Arepresents a valency bond or a -CH₂-group,  
as well as stereo and optically active isomers and their 

mixtures, acid-addition salts and quaternary ammonium derivatives 
thereof. 
1-(Phenyl)-3-[ω-(amino)-alkoxyimino]-alk-1-ene derivatives 

according to claim 1, characterized in that the C₁₋₄ alkyl 
group which may be represented by R₃ and/or the C₁₋₄ alkyl 

substituent by which the optional further nitrogen atom of 
the 4- to 7-membered heterocyclic ring which may be formed 

by R₄ and R₅ together with the nitrogen atom to which they 
are attached may be substituted and/or the C₁₋₄ alkoxy 

group(s) which may be represented by R₁ and/or R₂ is/are 
such having from 1 to 3, particularly 1 or 2, carbon 

atom(s) and/or the C₁₋₁₂ alkyl group(s) which may be represented 
by R₄ and/or R₅ is/are such having from 1 to 8, particularly 

1 to 4, carbon atom(s) and/or the C₁₋₈ alkyl group 
which may be represented by R is such having from 1 to 7, 

particularly 1 to 6, carbon atom(s) and/or the C₂₋₁₂ alkenyl 
group(s) which may be represented by R₄ and/or R₅ is/are 

such having from 2 to 6, particularly 2 to 4, carbon 
atom(s) and/or the 4- to 7-membered heterocyclic ring which 

may be formed by R₄ and R₅ together with the nitrogen atom 
to which they are attached is such having from 5 to 7, particularly 

5 or 6, carbon atoms, most particularly a morpholino, 
pyrrolidinyl, piperidinyl, piperazinyl, hexamethyleneimino 

or hexahydroazepinyl ring, and/or the halogen 
atom(s) which may be represented by R₁ and/or R₂ is/are 

chlorine, fluorine and/or bromine and/or the C₃₋₆ cycloalkyl 
 

group(s) which may be represented by R₄ and/or R₅ 
is/are such having 3, 5 or 6 carbon atoms. 
1-(Phenyl)-3-[ω-(amino)-alkoxyimino]-alk-1-ene derivatives 

according to claim 1 or 2, characterized in that 
R₁ and R₂independently each represents hydrogen 

or halogen, R₃stands for hydrogen or hydroxy, R₄ and R₅independently each represents C₁₋₄ alkyl 
   or R₄ and R₅together with the nitrogen atom to which 

they are attached form a piperidinyl or pyrrolidinyl 
group 

   and A and Rare as defined in claim 1 or 2. 
1-[Phenyl]-5-[methyl]
-3-(E)-[2'-(dimethylamino)-ethoxyimino]-1-(E)-hexene, 

1-[4'-(chloro)-phenyl]-6-[methyl]
-3-(E)-[3''-(N-{piperidinyl})-propoxyimino]-1-(E)-hexene, 

1-(4'-(chloro)-phenyl]-3-(E)-[2''-(N-{piperidinyl})-ethoxyimino]
-1-(E)-nonene, 
(R,S)-1-[4'-(chloro)-phenyl]
-6-[methyl]-3-(E)-[2''-(hydroxy)-3''-(piperidin-1'''-yl)-propoxyimino]
-1-(E)-heptene, 
1-[4'-(fluoro)-phenyl]
-6-[methyl]-3-(E)-[3''-(N-{piperidinyl})-propoxyimino]
-1-(E)-heptene,
 

1-[4'-(chloro)-phenyl]-6-[methyl]
-3-(Z)-[2''-(N-{methyl}-pyrrolidin-2'''-yl)-ethoxyimino]-1-(E)-heptene 

   and 
1-[4'-(chloro)-phenyl]
-6-[methyl]-3-(E)-[3''-(N-{pyrrolidinyl})-propoxyimino]
-1-(E)-heptene 
as well as stereo and optically active isomers, acid-addition 

salts and quaternary ammonium derivatives thereof. 
A process for preparing the compounds according to claims 1 
to 4, characterized in that in a manner known per se 


a) 1-(phenyl)-alk-1-ene-3-one or -3-thione derivatives of 
general formula 

 
wherein R₁, R₂ and R are as defined in claims 1 to 3 

and X stands for oxygen or sulfur, are reacted with 
substituted alkyl-0-hydroxylamines of general formula 


 
wherein D represents a group of formula H₂N-0-, 

R₆ stands for a group of formula 
 

in which latter R₄ and R₅ are as defined in claims 1 
to 3 and R₃ and A are as defined in claims 

1 to 3, or with the acid-addition salts thereof in the 
presence of a base 

   or 
b) for preparing compounds of general formula I, wherein 
R₃ represents hydrogen or C₁₋₄ alkyl and R, R₁ , R₂ , 

R₄ and R₅ are as defined in claims 1 to 3, 1-(phenyl)-alk-1-ene-3-oxime 
derivatives of general formula 

 
wherein R₁ , R₂ and R are as defined in claims 1 to 3 

and X' stands for a group of formula = N - OH, or 
acid-addition salts thereof are reacted with substitut
ed 
alkylhalides of general formula 


 
wherein D' stands for halogen, R₃ represents hydrogen 

or C₁₋₄ alkyl, R₆ is a group of formula 
 

in which latter R₄ and R₅ are as defined in claims 1 
to 3 and A is as defined in claim 1, or with acid-addition 

salts thereof in the presence of a basic condensing 
agent 

   or 
c) for preparing compounds of general formula I, 
wherein R₃ represents hydroxy, A stands for a group of 

formula - CH₂ - and R, R₁ , R₂ , R₄ and R₅ are as defined 
in claims 1 to 3, 1-(phenyl)-alk-1-ene-3-oxime 

derivatives of general formula II', wherein X' represents 
a group of formula = N - 0H and R₁ , R₂ and R 

are as defined in claims 1 to 3, or acid-addition 
salts thereof are reacted with 2,3-(epoxy)-propoxyhalides 

of general formula 
 

wherein D' represents halogen and A'', R₆'' and R₃'' together 
form a group of formula - CH₂ - 0 -, in the 

presence of a basic condensing agent, and the thus obtained 
1-(phenyl)-3-[2',3'-(epoxy)-propoxyimino]
-alk-1-enes 
of general formula  

wherein R₁ , R₂ and R are as defined in claims 1 to 3, 
are reacted with amines of general formula 

 
wherein R₇ stands for hydrogen, and R₄ and R₅ are as 

defined in claims 1 to 3 or in the presence of a basic 
agent with acid-addition salts of the former 

   or 
d) for preparing compounds of general formula I, wherein 
R₃ represents hydrogen or C₁₋₄ alkyl and R, R₁ , R₂ , 

R₄ , R₅ and A are as defined in claims 1 to 3, 1-(phenyl)-alk-1-ene-3-oxime 
derivatives of general formula 

II', wherein X' represents a group of formula 
= N - 0H and R₁ , R₂ and R are as defined in claims 1 

to 3, or acid-addition salts thereof are reacted with 
α,ω-dihalogenalkanes of general formula  

wherein D' stands for halogen, R₃ represents hydrogen 
or C₁₋₄ alkyl, R₆''' means halogen and A is as defined 

in claim 1, in the presence of a basic condensing 
agent and the thus obtained 1-(phenyl)-3-[ω-(halogen)-alkoxyimino]
-alk-1-ene 
derivatives of general formula 

 
wherein R₁ , R₂ , R₃ , R and A are as defined in claims 

1 to 3 and R₆''' is as defined for formula III''', are 
reacted with amines of general formula 

 
wherein R₇ stands for hydrogen, and R₄ and R₅ are as 

defined in claims 1 to 3, or with acid-addition salts 
thereof in the presence of a basic condensing agent 
 
and optionally in a manner known per se 1-(phenyl)-3-[ω-(amino)-alkoxyimino]
-alk-1-ene 
derivatives of general formula 

 
I thus obtained are converted into acid-addition salts 

or quaternary ammonium derivatives thereof or salts of 1-(phenyl)-3-[ω-(amino)-alkoxyimino]-alk-1-ene 

derivatives 
of general formula I thus obtained are converted into the 

free 1-(phenyl)-3-[ω-(amino)-alkoxyimino]-alk-1-ene derivative 

bases and/or into other acid-addition salts and/or 
mixtures or racemates of the above compounds of formula I 

are separated to the stereo and/or optically active isomers 
of the above compounds of formula I or the optically active 

isomers of the above compounds of formula I are racemised. 
A process according to claim 5 a), characterized in that 
the reaction is carried out in inert solvents or in mixtures 

of such solvents, particularly in an aliphatic alcohol, 
pyridine or triethylamine or in a mixture thereof. 
A process according to claim 5 b), characterized in that 
the reaction is carried out in inert solvents or mixtures 

of such solvents, particularly in an aliphatic alcohol, 
aromatic hydrocarbon, most particularly benzene or a homologue 

thereof, aliphatic or cyclic ether, most particularly 
dibutyl ether or tetrahydrofuran, or dimethyl acetamide or 

in a mixture thereof. 
A process according to claim 5 c) or d), characterized in 
that the reaction of the 1-(phenyl)-alk-1-ene-3-oxime derivatives 

of general formula II' with the 1-(phenyl)-3-[2',3'-(epoxy)-propoxyimino]-alk-1-enes 

of general formula 
III'' or α,ω-dihalogenalkanes of general formula III''', respectively, 

is carried out in inert or relatively inert 
solvents, particularly water, an aromatic hydrocarbon, most 

particularly benzene or toluene, or dimethylformamide or in 
a mixture thereof. 
Medicaments, characterized in that they contain as [an] 

active ingredient(s) at least one compound according to 
claims 1 to 4, suitably in admixture with at least one 

 
inert solid and/or liquid pharmaceutical carrier and/or 

diluent and/or excipient. 
Use of the compounds of claims 1 to 4 for preparing medicaments, 
particularly having ulcus and gastric-acid-secretion 

inhibiting and anxiolytic effects. 
</CLAIMS>
</TEXT>
</DOC>
